Target intelligence / Profile preview

Histone H3 lysine 27 trimethylation (H3K27me3)

Target
H3K27me3
Molecular classification
Histone modification
01

Overview

Histone H3 lysine 27 trimethylation (H3K27me3) is a critical repressive epigenetic mark that plays a fundamental role in chromatin organization, gene silencing, and transcriptional regulation. It is catalyzed primarily by the Polycomb Repressive Complex 2 (PRC2), where the methyltransferase Enhancer of Zeste Homolog 2 (EZH2) or its paralog EZH1 serves as the catalytic subunit. Conversely, the modification is removed by the Jumonji-domain-containing demethylases JMJD3 (KDM6B) and UTX (KDM6A). Aberrant hyper-trimethylation of H3K27 is a well-established hallmark of various malignancies, including lymphomas, leukemias, and solid tumors, where it leads to the epigenetic silencing of tumor suppressor and pro-differentiation genes. Pharmacological modulation of H3K27me3 has emerged as a powerful therapeutic strategy in oncology. Small-molecule inhibitors targeting EZH2 (such as tazemetostat) or dual EZH1/2 inhibitors (such as valemetostat and tulmimetostat) effectively reduce global H3K27me3 levels, thereby restoring the expression of silenced genes and promoting tumor cell differentiation or apoptosis. Additionally, embryonic ectoderm development (EED) inhibitors disrupt the PRC2 complex to achieve similar epigenetic reactivation. Conversely, demethylase inhibitors like GSK-J4 can be used to elevate H3K27me3 levels in specific contexts.

Other names
H3K27me3Trimethylated histone H3 lysine 27Histone H3 trimethyl lysine 27H3K27 trimethylationHistone H3 lysine 27 tri-methylation
02

Mechanism of action

Drugs modulate H3K27me3 levels by inhibiting the enzymes responsible for its deposition (writers) or removal (erasers), or by disrupting the protein-protein interactions required for its propagation. Specifically, EZH2/EZH1 inhibitors block the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) to prevent the transfer of methyl groups from S-adenosylmethionine (SAM) to H3K27, thereby reducing H3K27me3 levels and reactivating silenced genes. EED inhibitors bind to the H3K27me3-binding pocket of EED, disrupting PRC2 allosteric activation and leading to a loss of H3K27me3. Conversely, JMJD3/UTX demethylase inhibitors block the removal of methyl groups, thereby increasing H3K27me3 levels.

03

Biological functions

Epigenetic regulationTranscriptional repressionGene silencingChromatin condensationCell differentiationCell proliferationApoptosis
04

Disease associations

CancerInflammationCardiovascular diseaseNeurodegenerative disease
05

Safety considerations

Myelosuppression (neutropenia, thrombocytopenia, anemia)Secondary malignancies (e.g., T-cell lymphoblastic lymphoma)Risk of resistance due to secondary mutations in EZH2 or EEDOff-target effects on normal stem cell differentiation and tissue homeostasisIncomplete target coverage leading to compensatory upregulation of EZH1
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

H3K27me3 levels in tumor tissueEZH2 mutation statusSMARCB1/INI1 deficiencyARID1A mutation statusH3K27M mutation status

Beyond the preview

Go deeper on Histone H3 lysine 27 trimethylation (H3K27me3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone H3 lysine 27 trimethylation (H3K27me3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call